share_log

Apollomics | 6-K: Report of foreign private issuer (related to financial reporting)

Apollomics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Apollomics | 6-K：外国发行人报告
SEC announcement ·  03/28 07:09
Moomoo AI 已提取核心信息
On March 28, 2024, Apollomics Inc., a late-stage clinical biopharmaceutical company, announced its full-year financial results for 2023 and provided updates on its clinical progress. The company reported a cash position of $37.8 million as of December 31, 2023, with a projected cash runway through the first quarter of 2025. Apollomics highlighted significant advancements in its vebreltinib program for non-small cell lung cancer and other solid tumors with MET dysregulation. The company also completed patient enrollment for a Phase 3 bridging study in China for uproleselan, an E-selectin inhibitor, with topline data expected in the first half of 2025. Research and development expenses for the year were $34.2 million, and general and administrative expenses were $20.6 million. The net loss for the year was $(172.6) million, or $(2.32) per diluted share. The company also held a conference call to discuss these results and provide a corporate update.
On March 28, 2024, Apollomics Inc., a late-stage clinical biopharmaceutical company, announced its full-year financial results for 2023 and provided updates on its clinical progress. The company reported a cash position of $37.8 million as of December 31, 2023, with a projected cash runway through the first quarter of 2025. Apollomics highlighted significant advancements in its vebreltinib program for non-small cell lung cancer and other solid tumors with MET dysregulation. The company also completed patient enrollment for a Phase 3 bridging study in China for uproleselan, an E-selectin inhibitor, with topline data expected in the first half of 2025. Research and development expenses for the year were $34.2 million, and general and administrative expenses were $20.6 million. The net loss for the year was $(172.6) million, or $(2.32) per diluted share. The company also held a conference call to discuss these results and provide a corporate update.
2024年3月28日，后期临床生物制药公司Apollomics Inc. 公布了其2023年全年财务业绩，并提供了其临床进展的最新情况。该公司报告称，截至2023年12月31日，现金状况为3,780万美元，预计现金流将持续到2025年第一季度。Apollomics强调了其针对非小细胞肺癌和其他有MET失调的实体瘤的vebreltinib项目取得了重大进展。该公司还完成了在中国进行的e-Selectin抑制剂uproleselan的3期桥接研究的患者入组，预计将在2025年上半年公布头条数据。该年度的研发费用为3,420万美元，一般和管理费用为2,060万美元。该年度的净亏损为1.726亿美元，摊薄后每股亏损2.32美元。该公司还举行了电话会议，讨论这些结果并提供了公司最新情况。
2024年3月28日，后期临床生物制药公司Apollomics Inc. 公布了其2023年全年财务业绩，并提供了其临床进展的最新情况。该公司报告称，截至2023年12月31日，现金状况为3,780万美元，预计现金流将持续到2025年第一季度。Apollomics强调了其针对非小细胞肺癌和其他有MET失调的实体瘤的vebreltinib项目取得了重大进展。该公司还完成了在中国进行的e-Selectin抑制剂uproleselan的3期桥接研究的患者入组，预计将在2025年上半年公布头条数据。该年度的研发费用为3,420万美元，一般和管理费用为2,060万美元。该年度的净亏损为1.726亿美元，摊薄后每股亏损2.32美元。该公司还举行了电话会议，讨论这些结果并提供了公司最新情况。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息